Latest & greatest articles for finasteride

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on finasteride or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on finasteride and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for finasteride

1. Finasteride

Finasteride Top results for finasteride - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box (...) and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for finasteride The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical

Trip Latest and Greatest2018

2. Finasteride: rare reports of depression and suicidal thoughts

Finasteride: rare reports of depression and suicidal thoughts Finasteride: rare reports of depression and suicidal thoughts - GOV.UK GOV.UK uses cookies to make the site simpler. Search Finasteride: rare reports of depression and suicidal thoughts From: Published: 24 May 2017 Therapeutic area: , , and We have received reports of depression and, in rare cases, suicidal thoughts in men taking finasteride 1 mg (Propecia) for male pattern hair loss. Be aware that depression is also associated (...) with finasteride 5 mg (Proscar). Contents Advice for healthcare professionals: since finasteride has been marketed there have been a number of spontaneous adverse drug reaction reports suggesting a possible link to depression, and in rare cases, suicidal thoughts advise patients to stop finasteride 1 mg (Propecia) immediately if they develop depression and inform a healthcare professional be aware that the product information for finasteride 5 mg (Proscar) already lists depression as a possible adverse

MHRA Drug Safety Update2017

3. Dutasteride and finasteride for men with benign prostatic hyperplasia: comparative clinical effectiveness and safety

Dutasteride and finasteride for men with benign prostatic hyperplasia: comparative clinical effectiveness and safety Dutasteride and finasteride for men with benign prostatic hyperplasia: comparative clinical effectiveness and safety Dutasteride and finasteride for men with benign prostatic hyperplasia: comparative clinical effectiveness and safety CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation CADTH. Dutasteride and finasteride for men with benign prostatic hyperplasia: comparative clinical effectiveness and safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary of Abstracts. 2014 Authors' conclusions Four systematic reviews and six randomized controlled trials were found regarding the clinical effectiveness and safety of dutasteride and finasteride compared to each other or placebo

Health Technology Assessment (HTA) Database.2014

5. Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer

Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer Reed SD, Scales CD, Stewart SB, Sun J, Moul JW, Schulman KA, Xu J Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of chemoprevention of prostate cancer using finasteride, compared with no chemoprevention, considering risk groups. At a threshold of 100,000 US dollars per quality-adjusted life

NHS Economic Evaluation Database.2011

6. Finasteride: potential risk of male breast cancer

Finasteride: potential risk of male breast cancer Finasteride: potential risk of male breast cancer Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Finasteride: potential risk of male breast cancer From: Published: 1 December 2009 Therapeutic area: and Patients should be advised to promptly report to their doctor any changes in their breast tissue such as lumps, pain, or nipple discharge. Article date: December 2009 Finasteride is an inhibitor of type II 5α (...) -reductase, an enzyme that metabolises testosterone into the more potent androgen, dihydrotestosterone (DHT), resulting in a reduction in DHT concentrations in serum and target tissues. 5 mg finasteride (Proscar) is used for the treatment and control of benign prostatic hyperplasia because enlargement of the prostate gland is dependent on conversion of testosterone to DHT. Finasteride can also reduce scalp and serum DHT concentrations, and the 1 mg dose (Propecia) is indicated for the treatment of men

MHRA Drug Safety Update2010

7. Outcomes Associated With the Use of Finasteride: An Evaluation of this Medication as a Chemoprotective Agent and its Efficacy

Outcomes Associated With the Use of Finasteride: An Evaluation of this Medication as a Chemoprotective Agent and its Efficacy "Outcomes Associated With the Use of Finasteride: An Evaluation of this" by Catherine H. Cieslik < > > > > > Title Author Date of Award 8-14-2010 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Latha Reddy Second Advisor Annjanette Sommers MS, PAC Third Advisor Rob Rosenow PharmD, OD Rights . Abstract Background (...) : Whether a male should be placed on a well-studied pharmaceutical agent thought to have chemoprotective properties, is currently a question that is debated by clinicians. The purpose of this study is to determine the benefits versus harms associated with finasteride as a chemoprotective agent. Finasteride, has been used for the treatment of benign prostatic hyperplasia. It has been hypothesized that, since this medication resulted in the reduction of PSA levels, and a decrease in the size

Pacific University EBM Capstone Project2010

9. Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer

Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer Zeliadt S B, Etzioni R D, Penson D F, Thompson I M, Ramsey S D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the use of the 5-alpha-reductase inhibitor finasteride (5 mg/day) for the prevention of prostate cancer. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis and cost-utility analysis. Study population The model analysed data for a hypothetical cohort of men aged 55 years who commenced

NHS Economic Evaluation Database.2005

10. Finasteride reduced prostate cancer but led to more high grade tumours and sexual side effects

Finasteride reduced prostate cancer but led to more high grade tumours and sexual side effects Finasteride reduced prostate cancer but led to more high grade tumours and sexual side effects | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Finasteride reduced prostate cancer but led to more high grade tumours and sexual side effects Article Text Therapeutics Finasteride reduced prostate cancer but led to more high grade tumours and sexual side effects Free John C Morris III , MD Statistics from Altmetric.com No Altmetric data available for this article

Evidence-Based Medicine (Requires free registration)2004

11. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia

An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia McDonald H, Hux M, Brisson M, Bernard L, Nickel J C Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined finasteride (FIN), a 5-alpha-reductase inhibitor, either alone or in combination with doxazosin (DOX), an alpha-blocker, for the treatment of benign prostate hyperplasia (BPH). The doses used were 5 mg FIN once daily and 4 mg DOX once daily. Type

NHS Economic Evaluation Database.2004

12. The influence of finasteride on the development of prostate cancer.

The influence of finasteride on the development of prostate cancer. 12824459 2003 07 17 2003 07 22 2014 06 09 1533-4406 349 3 2003 Jul 17 The New England journal of medicine N. Engl. J. Med. The influence of finasteride on the development of prostate cancer. 215-24 Androgens are involved in the development of prostate cancer. Finasteride, an inhibitor of 5alpha-reductase, inhibits the conversion of testosterone to dihydrotestosterone, the primary androgen in the prostate, and may reduce (...) the risk of prostate cancer. In the Prostate Cancer Prevention Trial, we randomly assigned 18,882 men 55 years of age or older with a normal digital rectal examination and a prostate-specific antigen (PSA) level of 3.0 ng per milliliter or lower to treatment with finasteride (5 mg per day) or placebo for seven years. Prostate biopsy was recommended if the annual PSA level, adjusted for the effect of finasteride, exceeded 4.0 ng per milliliter or if the digital rectal examination was abnormal

NEJM2003

13. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. 14681504 2003 12 18 2003 12 23 2013 11 21 1533-4406 349 25 2003 Dec 18 The New England journal of medicine N. Engl. J. Med. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. 2387-98 Benign prostatic hyperplasia is commonly treated with alpha-adrenergic-receptor antagonists (alpha (...) -blockers) or 5alpha-reductase inhibitors. The long-term effect of these drugs, singly or combined, on the risk of clinical progression is unknown. We conducted a long-term, double-blind trial (mean follow-up, 4.5 years) involving 3047 men to compare the effects of placebo, doxazosin, finasteride, and combination therapy on measures of the clinical progression of benign prostatic hyperplasia. The risk of overall clinical progression--defined as an increase above base line of at least 4 points

NEJM2003

14. Direct To Consumer Advertising: Finasteride for male pattern hair loss

Direct To Consumer Advertising: Finasteride for male pattern hair loss [40] Direct To Consumer Advertising: Finasteride for male pattern hair loss | Therapeutics Initiative Independent Healthcare Evidence > > [40] Direct To Consumer Advertising: Finasteride for male pattern hair loss Case: Mr. Jones (26 years old) comes in to see you about a cough he has had for 3-4 weeks. You’ve just finished listening to his chest and reassured him that it’s the aftermath of a viral infection. He asks you (...) ), finasteride (Propecia ® , $100 million) , sildenafil (Viagra ® , $94 million), omeprazole (Prilosec ® , $80 million), and orlistat (Xenical ® , $76 million). Sales The 25 top-selling DTCA drugs accounted for 40.7%, or $7.2 billion, of the overall $17.7 billion (19%) increase in drug sales (retail) in 1999 over 1998. Doctors wrote 34.2% more prescriptions in 1999 than in 1998 for the top 25 DTCA drugs. Doctors wrote only 5.1% more prescriptions for all other prescription drugs. What should clinicians do

Therapeutics Letter2001

15. Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia

Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia Wilde MI, Goa KL Authors' objectives To overview the pharmacology of finasteride and provide an update of its clinical effects in patients with benign prostatic hyperplasia. Searching MEDLINE, EMBASE (...) and AdisBase (a proprietary database of Adis International, Auckland, New Zealand) were searched for trials published in any language since 1966 until February 1999. Search terms included finasteride combined with either prostatic hypertrophy or benign prostatic hyperplasia. Bibliographic information, including contributory unpublished data was also requested from the company developing the drug. Study selection Study designs of evaluations included in the review Inclusion of studies was mainly based

DARE.1999

16. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. 9475762 1998 02 26 1998 02 26 2013 11 21 0028-4793 338 9 1998 Feb 26 The New England journal of medicine N. Engl. J. Med. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy (...) and Safety Study Group. 557-63 Finasteride is known to improve urinary symptoms in men with benign prostatic hyperplasia, but the extent to which the benefit is sustained and whether finasteride reduces the incidence of related events, including the need for surgery and the development of acute urinary retention, is not known. In this double-blind, randomized, placebo-controlled trial, we studied 3040 men with moderate-to-severe urinary symptoms and enlarged prostate glands who were treated daily with 5

NEJM1998

17. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials

Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials Boyle P, Gould A L, Roehrborn C G Authors' objectives To examine whether (...) prostate size could predict the outcome of finasteride treatment, and therefore, indicate which men should be the best candidates for finsasteride therapy. Searching The authors do not provide details of the sources searched or the strategies employed. Study selection Study designs of evaluations included in the review Randomised, multicentre, placebo-controlled clinical trials of at least 12 months' duration were included. Specific interventions included in the review Terazosin, finasteride (5 mg

DARE.1996

18. An economic evaluation of finasteride for treatment of benign prostatic hyperplasia

An economic evaluation of finasteride for treatment of benign prostatic hyperplasia An economic evaluation of finasteride for treatment of benign prostatic hyperplasia An economic evaluation of finasteride for treatment of benign prostatic hyperplasia Baladi J F, Menon D, Otten N Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Using 5 alpha-reductase inhibitor finasteride versus transurethral resection of the prostate (TURP), and watchful waiting (periodic monitoring of a patient by his physician, representing the "do nothing" option) in the treatment of patients (older men) with benign prostatic hyperplasia (BPH). Type of intervention Treatment. Economic study type Cost-effectiveness analysis and cost-utility analysis

NHS Economic Evaluation Database.1996

19. Finasteride: clinical and economic impacts

Finasteride: clinical and economic impacts Finasteride: clinical and economic impacts Finasteride: clinical and economic impacts Otten N Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology A new medical treatment (...) for benign prostatic hypertrophy (BPH), finasteride, was compared with the two most common treatment options that is transurethral resection of the prostate (TURP) and watchful waiting, for patients with varying degrees of symptom severity. Type of intervention Treatment; secondary prevention. Economic study type Cost-effectiveness analysis and cost-utility analysis. Study population Males receiving either finasteride, TURP or watchful waiting for the treatment of BPH. Patients had either mild, moderate or severe symptoms

NHS Economic Evaluation Database.1996

20. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. 8684407 1996 08 22 1996 08 22 2013 11 21 0028-4793 335 8 1996 Aug 22 The New England journal of medicine N. Engl. J. Med. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. 533-9 Men with benign prostatic hyperplasia can (...) be treated with alpha 1-adrenergic-antagonist drugs that relax prostatic smooth muscle or with drugs that inhibit 5 alpha-reductase and therefore reduce tissue androgen concentrations. However, the effects of the two types of drugs have not been compared. We compared the safety and efficacy of placebo, terazosin (10 mg daily), finasteride (5 mg daily), and the combination of both drugs in 1229 men with benign prostatic hyperplasia. American Urological Association symptom scores and peak urinary-flow

NEJM1996